Form 8-K - Current report:
SEC Accession No. 0001493152-25-002145
Filing Date
2025-01-14
Accepted
2025-01-14 16:15:25
Documents
19
Period of Report
2025-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56857
2 ex10-1.htm EX-10.1 257488
3 ex10-2.htm EX-10.2 102967
4 ex10-3.htm EX-10.3 107821
5 ex10-4.htm EX-10.4 107246
6 ex99-1.htm EX-99.1 12227
7 ex99-1_001.jpg GRAPHIC 9272
  Complete submission text file 0001493152-25-002145.txt   953106

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE indp-20250112.xsd EX-101.SCH 3021
9 XBRL LABEL FILE indp-20250112_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE indp-20250112_pre.xml EX-101.PRE 24169
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3459
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40652 | Film No.: 25529545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)